PAH Treatment Trends and Market Assessment
April 2010
Project Objectives:
n Primary Objective: To understand current practices and trends in the treatment of pulmonary arterial hypertension (PAH)
Study Scope and Participants:
n Specialties and quotas:
· 50 pulmonologists
n Screening Criteria:
· US-based pulmonologists
· Board-certified in specialty
· 2 to 30 years of experience post-training
· Minimum of 75% professional time spent in clinical practice
· Treats at least 10 patients/month for PAH
· Treats WHO Group I patients
Deliverables: Survey Data Only
Price: $2500
Please contact Howard.Brick@medpanel.com to purchase
Screening Questions
S1. What is your primary medical specialty?
¡ Rheumatology [terminate]
¡ Gastroenterology [terminate]
¡ Dermatology [terminate]
¡ Pulmonology
¡ Oncology [terminate]
¡ Other, please specify [Terminate]
S2. Are you board certified in your specialty?
¡ Yes
¡ No [Terminate]
S3. Approximately how many years have you been in practice post-training?
Years [Terminate <2 or >30]
S4. Approximately what percentage of your professional time is spent in clinical practice?
% of my professional time [Terminate <75%]
S5. Please select the setting which best describes where you spend most of your time in clinical practice.
¡ Academic/teaching hospital
¡ Community hospital
¡ Group practice – single specialty
¡ Group practice – multi-specialty
¡ Private practice
S6. Please indicate the number of patients you treat for pulmonary arterial hypertension (PAH) in a typical month:
_________ patients/month [terminate if <10]
S7. Of these
_________ patients/month [terminate if <1]
(Standard Qualify Text)
PAH Treatment Trends and Market Assessment
SECTION ONE: Current Market
1. How many patients are you currently treating for PAH?
_______ patients
2. Of these
|
Type |
Number of PAH Patients |
|
NYHA Class II |
|
|
NYHA Class III |
|
|
NYHA Class IV |
|
3. Within each of these classes, how many patients are treated with the following regimens?
|
Regimen |
Number of Class II PAH Patients |
Number of Class III PAH Patients |
Number of Class IV PAH Patients |
Total Number of Patients on Regimen |
|
Phosphodiesterase-5 inhibitor (PDE5) |
|
|
|
|
|
Endothelin receptor antagonist (ERA) |
|
|
|
|
|
Prostacyclin |
|
|
|
|
|
PDE5 + ERA |
|
|
|
|
|
PDE5 + Prostacyclin |
|
|
|
|
|
ERA + Prostacyclin |
|
|
|
|
|
PDE5 + ERA + Prostacyclin |
|
|
|
|
|
Other, please specify:______ |
|
|
|
|
|
TOTAL |
|
|
|
|
4. Of the patients who are treated with prostacyclins, how many are specifically using Tyvaso? (Note: we have inserted the total number of patients currently treated with each regimen involving prostacyclins you reported in the previous question as a reference.)
|
Regimen |
Total Number of Patients on Regimen |
Number of Patients Specifically Using Tyvaso |
|
Prostacyclin |
|
(force |
|
PDE5 + Prostacyclin |
|
(force |
|
ERA + Prostacyclin |
|
(force |
|
PDE5 + ERA + Prostacyclin |
|
(force |
5. Of the patients you are currently treating with Tyvaso, what percentage is:
|
Line of Treatment |
% of Patients Currently Treated With Tyvaso |
|
Newly diagnosed patients undergoing first-line treatment |
______% |
|
Patients undergoing second-line or more therapy after prior treatment with: | |
|
Revatio (sildenafil) |
______% |
|
Adcirca (tadalafil) |
______% |
|
Letairis (ambrisentan) |
______% |
|
Tracleer (bosentan) |
______% |
|
Ventavis (iloprost) |
______% |
|
SC Remodulin (treprostinil sodium) |
______% |
|
IV Remodulin (treprostinil sodium) |
______% |
|
IV Flolan (Epoprostenol sodium) |
______% |
|
Any combination therapy, please specify:_____ |
______% |
|
Other, please specify:_______ |
______% |
5. Are you aware of the results of the FREEDOM-C Phase III study for oral Remodulin?
¡ Yes
¡ No
6. Assuming the FDA approves the use of oral Remodulin for PAH in the future, please predict how effective it would be as a monotherapy:
|
Not at all effective |
|
Somewhat effective |
|
Very effective |
|
1 |
2 |
3 |
4 |
5 |
|
¡ |
¡ |
¡ |
¡ |
¡ |
7. Assuming the FDA approves the use of oral Remodulin for PAH in the future, please predict how effective it would be in combination with other therapies:
|
Not at all effective |
|
Somewhat effective |
|
Very effective |
|
1 |
2 |
3 |
4 |
5 |
|
¡ |
¡ |
¡ |
¡ |
¡ |
8. How would you incorporate oral Remodulin in your PAH treatment practices? (Please assume FDA approval.)
¡ Only as a monotherapy
¡ Only in combination with other therapies (skip to q10)
¡ Both as a monotherapy and in combination with other therapies
¡ I would not use oral Remodulin (skip to q10)
9. What would you most likely combine oral Remodulin with? Please specify which NYHA patient class you would treat with this combination therapy. (open-end)
(END survey)
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Pulmonology |